China API Alert, Indian Firms Brace For More Pain
Executive Summary
Prices of active pharmaceutical ingredients and intermediates from China have gone up significantly, piling pressure on Indian and Western companies that rely on it for supplies. Some firms are scrambling to draw up a plan B to secure supplies as the Asian giant weeds out polluting units and ups compliance.
You may also be interested in...
Coronavirus API Supply Impact A ‘Big Wake Up Call’ For India
Satish Reddy, president of the Indian Pharmaceutical Alliance and chair of Dr Reddy’s Laboratories, says that the government and domestic industry have to act promptly, and in tandem, to regain India’s glory days of dominance in active pharmaceutical ingredients and avoid a public health problem.
IPA Chief Reddy: Coronavirus API Supply Impact A ‘Big Wake Up Call’ For India
Satish Reddy, president of the Indian Pharmaceutical Alliance and chair of Dr Reddy’s Laboratories, tells Scrip in an interview that the government and domestic industry have to act promptly, and in tandem, to regain India’s glory days of dominance in active pharmaceutical ingredients and avoid a public health problem.
Indian Pharma Monitoring Coronavirus Fallout On Production
With several Chinese manufacturing facilities shut at least till 10 February, Indian pharma companies are keeping a close watch on the evolving coronavirus situation. API inventory can last for a while, but if intermediates supplies don’t resume soon the fallout could be grim.